α-Synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide

Neurochemistry International

Volumn 49, Issue 4, 2006, Pages 407-412

  Adamczyk, Agata ^a   Kaźmierczak, Anna ^a   Strosznajder, Joanna B ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Alpha synuclein; Dopamine transporter; Nitric oxide; Striatum

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; DICHLORODIHYDROFLUORESCEIN DIACETATE; DOPAMINE; DOPAMINE TRANSPORTER; FERROUS CHLORIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; TROLOX C;

AGING; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOWN REGULATION; HOMEOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOCHEMISTRY; RAT; SPECTROFLUOROMETRY; STATISTICAL SIGNIFICANCE;

AGING; ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; CELL MEMBRANE; CYTOSOL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; LIPID PEROXIDATION; MALE; NEOSTRIATUM; NEUROTOXINS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE I; NITROPRUSSIDE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SYNAPTOSOMES;

EID: 33746330776     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.01.025     Document Type: Article

References (36)

1. Asakawa T., and Matsushita S. Coloring conditions of thiobarbituric acid test for detecting lipid hydroperoxides. Lipids 15 (1980) 137-140
2. Barc S., Page G., Barrier L., Piriou A., and Fauconneau B. Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors. Neurosci. Lett. 314 (2001) 82-86
3. Barrier L., Barc S., Fauconneau B., Pontcharraud R., Kelani A., Bestel E., and Page G. Evidence that acidosis alters the high-affinity dopamine uptake in rat striatal slices and synaptosomes by different mechanisms partially related to oxidative damage. Neurochem. Int. 42 (2003) 27-34
4. Bodles A.M., Guthrie D.J., Harriott P., Campbell P., and Irvine G.B. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem. 267 (2000) 2186-2194
5. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., and Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287 (2000) 65-67
6. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury P.T. Kinetic stabilization of the a-synuclein protofibril by a dopamine-a-synuclein adduct. Science 294 (2001) 1346-1349
7. El-Agnaf O.M., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D., and Wallace A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440 (1998) 71-75
8. Giasson B.I., Murray I.V., Trojanowski J.Q., and Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001) 2380-2386
9. 3H]dopa in various regions of the brain. J. Neurochem. 8 (1966) 655-669
10. Goldberg M.S., and Lansbury Jr. P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2 (2000) 115-119
11. Graham D.G., Tiffany S.M., Bell Jr. W.R., and Gutknecht W.F. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978) 644-653
12. Kiss J.P., Zsilla G., and Vizi E.S. Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. Neurochem. Int. 45 (2004) 485-489
13. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
14. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., and Lansbury Jr. P.T. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322 (2002) 1089-1102
15. Lee F.J., Liu F., Pristupa Z.B., and Niznik H.B. Direct binding and functional coupling of a-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15 (2001) 916-926
16. 3H]glutamate by striatal synaptosomes. J. Neurochem. 63 (1994) 2108-2117
17. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
18. Maker H.S., Weiss C., Silides D.J., and Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36 (1981) 589-593
19. Morel P., Fauconneau B., Page G., Mirbeau T., and Huguet F. Inhibitory effects of ascorbic acid on dopamine uptake by rat striatal synaptosomes: relationship to lipid peroxidation and oxidation of protein sulfhydryl groups. Neurosci. Res. 32 (1998) 171-179
20. Park S.U., Ferrer J.V., Javitch J.A., and Kuhn D.M. Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J. Neurosci. 22 (2002) 4399-4405
21. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. A role for a-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22 (2002) 3090-3099
22. Perez R.G., and Hastings T.G. Could a loss of a-synuclein function put dopaminergic neurons at risk?. J. Neurochem. 89 (2004) 1318-1324
23. Salvatore M.F., Apparsundaram S., and Gerhardt G.A. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol. Aging 24 (2003) 1147-1154
24. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
25. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., Park C.H., Kim S., Kim E.M., Lee S.H., Lee S., Suh S.W., and Suh Y.H. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16 (2002) 1826-1828
26. Sidhu A., Wersinger C., and Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 18 (2004) 637-647
27. Strosznajder J.B., and Chalimoniuk M. Biphasic enhancement of nitric oxide synthase activity and cGMP level following brain ischemia in gerbils. Acta Neurobiol. Exp. 56 (1996) 71-81
28. Sung J.Y., Kim J., Paik S.R., Park J.H., Ahn Y.S., and Chung K.C. Induction of neuronal cell death by Rab5A-dependent endocytosis of a-synuclein. J. Biol. Chem. 276 (2001) 27441-27448
29. Sung J.Y., Park S.M., Lee C.H., Um J.W., Lee H.J., Kim J., Oh Y.J., Lee S.T., Paik S.R., and Chung K.C. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 280 (2005) 25216-25224
30. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., and Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11282-11286
31. Volles M.J., and Lansbury Jr. P.T. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41 (2002) 4595-4602
32. Wersinger C., Prou D., Vernier P., and Sidhu A. Modulation of dopamine transporter function by a-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17 (2003) 2151-2153
33. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
34. Yu S., Ueda K., and Chan P. Alpha-synuclein and dopamine metabolism. Mol. Neurobiol. 31 (2005) 243-254
35. 2+- and cholinergic receptor-mediated phosphoinositide degradation by alteration of membrane and cytosolic phospholipase C in brain cortex. Neurochem. Res. 25 (2000) 189-196
36. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., and Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005) 533-542